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ABSTRACT:
Glioblastoma remains one of the deadliest of human cancers, with most patients 
succumbing to the disease within two years of diagnosis. The available data suggest 
that simultaneous inactivation of critical nodes within the glioblastoma molecular 
circuitry will be required for meaningful clinical efficacy. We conducted parallel 
genome-wide shRNA screens to identify such nodes and uncovered a number of 
G-Protein Coupled Receptor (GPCR) neurotransmitter pathways, including the 
Dopamine Receptor D2 (DRD2) signaling pathway. Supporting the importance of 
DRD2 in glioblastoma, DRD2 mRNA and protein expression were elevated in clinical 
glioblastoma specimens relative to matched non-neoplastic cerebrum. Treatment 
with independent si-/shRNAs against DRD2 or with DRD2 antagonists suppressed the 
growth of patient-derived glioblastoma lines both in vitro and in vivo. Importantly, 
glioblastoma lines derived from independent genetically engineered mouse models 
(GEMMs) were more sensitive to haloperidol, an FDA approved DRD2 antagonist, 
than the premalignant astrocyte lines by approximately an order of magnitude. The 
pro-proliferative effect of DRD2 was, in part, mediated through a GNAI2/Rap1/
Ras/ERK signaling axis. Combined inhibition of DRD2 and Epidermal Growth Factor 
Receptor (EGFR) led to synergistic tumoricidal activity as well as ERK suppression in 
independent in vivo and in vitro glioblastoma models. Our results suggest combined 
EGFR and DRD2 inhibition as a promising strategy for glioblastoma treatment.
INTRODUCTION 
Glioblastoma is the most common form of brain 
cancer, with approximately 10,000 new cases per year 
in the U.S.[1, 2].The disease is characterized by invasive 
growth patterns, rendering complete surgical resection 
impossible [3]. Moreover, glioblastoma is highly resistant 
to conventional chemotherapy and radiation therapy 
[4, 5], with recurrence nearly universal.  The median 
survival of patients afflicted with glioblastoma remains 
approximately 14 months [2].  Novel therapeutic strategies 
are desperately needed.Oncotarget 883 www.impactjournals.com/oncotarget
Identification  of  oncogenic  driver  proteins 
responsible for glioblastoma formation and the 
development of inhibitors against these proteins have led 
to interests in molecularly targeted therapies [6]. One of 
the best characterized glioblastoma proto-oncogenes is the 
Epidermal Growth Factor Receptor (EGFR). While EGFR 
is frequently mutated or amplified during glioblastoma 
pathogenesis [7, 8], clinical experiences with EGFR 
inhibitors have been disappointing [9]. Subsequent studies 
suggest that glioblastomas possess dynamic molecular 
circuits, such that EGFR mediated functions can be 
substituted by activation of alternate pathways [10-16]. 
In this context, many have proposed that simultaneous 
inactivation of critical nodes within the molecular circuitry 
will be required for meaningful clinical efficacy [4, 14].
Here, we conducted parallel genome-wide 
shRNA screens to identify the critical nodes within the 
glioblastoma molecular circuitry. We identified a number 
of G-Protein Coupled Receptor (GPCR) neurotransmitter 
pathways, including Dopamine Receptor D2 (DRD2). 
We demonstrate that dopamine antagonists harbor anti-
glioblastoma activity that is synergistic when combined 
with EGFR inhibition. Our data suggest that FDA-
approved DRD2 antagonists, such as haloperidol, warrant 
consideration as potential glioblastoma therapy.
RESULTS AND DISCUSSION
To identify key nodes required for glioblastoma 
proliferation, we conducted a genome-wide retroviral 
shRNA library screen [17, 18] in two glioblastoma cell 
lines (U87MG and A172) and two lung carcinoma lines 
(A549 and H460) (Figure 1A). Screen results from 
independent experiments performed on separate days 
were highly reproducible (Figure 1B). The targets of the 
top 1,000 shRNAs that compromised the proliferation of 
both U87MG and A172 without affecting A549 or H460 
growth were analyzed by PANTHER [19]. The analysis 
revealed a number of pathways previously implicated in 
regulating cell proliferation and renewal, including PDGF 
and Wnt [20]. The analysis additionally revealed genes 
involved in G-protein coupled neurotransmitter receptors 
(GPCR) signaling (Figure 1C and D). The DRD2 pathway 
was selected for further characterization because of: i) the 
availability of FDA-approved DRD2 antagonists, such as 
haloperidol, that cross the blood-brain barrier [21] and 
may be repurposed for glioblastoma therapy; ii) findings 
from previous unbiased chemical screens suggesting that 
DRD2 antagonists harbor anti-leukemia activity [22], and 
that such activities may be pertinent to glioblastomas; and 
iii) previous reports documenting that DRD2 signaling 
activates MAPK [23-25], and this signaling may 
contribute to glioblastoma growth [6]. 
We  first  validated  our  screen  results  using 
independent sh- and siRNAs against DRD2 (Figure 1E).   
In all instances, DRD2 silencing compromised U87MG 
glioblastoma growth by 70-90%. At concentrations that 
did not impair the growth of Normal Human Astrocytes 
(NHA) or the H460 lung cancer line, haloperidol caused 
a 50-70% viability reduction in both long-term passaged 
glioblastoma lines and glioblastoma stem cell (GSC) lines 
(Figure 1F). These results were recapitulated using three 
additional DRD2 antagonists (Figure 1G). 
In vivo, DRD2 shRNA (shDRD2) expression 
suppressed U87MG subcutaneous xenograft growth. 
Mice were implanted with U87MG harboring a 
doxycycline-inducible shDRD2 construct (dox-shDRD2) 
and randomized to doxycycline-containing or control 
water. By week 6, the average xenograft volume in the 
doxycycline-treated mice was <1% of that in the vehicle-
treated mice (Figure 1H). Importantly, expression of an 
RNAi-Resistant DRD2 construct (DRD2RR) rescued 
doxycycline-induced the growth-suppressive effect of 
shDRD2 in this in vivo model (Figure 1I). Xenograft 
formation was noted by week 15 in doxycycline-treated 
mice that were implanted with U87MG co-expressing dox-
shDRD2 and DRD2RR. The growth of these xenografts 
was slower than that observed for U87MG, suggesting 
that the phenotypic rescue by DRD2RR was likely 
incomplete [26, 27]. In contrast, mice harboring U87MG 
co-expressing dox-shDRD2 and wild-type DRD2 showed 
minimal tumor growth when fed doxycycline. These 
results suggest the tumoricidal effect of DRD2 silencing 
was unlikely the result of off-target effects [28].  
We next determined whether DRD2 was over-
expressed in glioblastoma specimens. Relative to tumor-
adjacent cerebrum, all glioblastoma specimens showed a 
4-17 fold increase in DRD2 mRNA (Figure 2A) or 2-4 
fold enhancement in protein expression (Figure 2B). We 
further tested whether DRD2 expression was associated 
with any particular molecular subtypes of glioblastoma in 
The Cancer Genome Atlas (TCGA), but did not identify 
any specific association (Supplemental Figure 1) [7].
Consistent with observations derived from clinical 
specimens, DRD2 was highly expressed in GEMM derived 
glioblastoma lines. DRD2 expression was 14-fold higher 
in a glioblastoma line derived from an hGFAP-Cre+;   
p53-/-;  NF1flox/flox GEMM relative to an astrocytic line 
derived from an isogenic hGFAP-Cre+; NF1flox/flox GEMM 
[29]. In an independent model, DRD2 expression was 
6-fold higher in a glioblastoma neurosphere line derived 
from an hGFAP-Cre+; p53lox/lox; Ptenlox/+ GEMM relative 
to an astrocytic neurosphere line derived from an isogenic 
hGFAP-Cre+; p53lox/lox GEMM [30] (Figure 2C). Further, 
in vivo glioblastoma specimens derived from a GEMM 
where  Gtv-a Ink4a-Arf-/- mice were stereotactically 
injected with RCAS-PDGFB-HA [31] exhibited 20-40 
fold increases in DRD2 expression relative to matched 
contra-lateral cortex (Figure 2D). 
Importantly, the increased DRD2 expression in 
glioblastomas was accompanied by a dependence on 
DRD2 for viability. Haloperidol reduced the viability Oncotarget 884 www.impactjournals.com/oncotarget
of a glioblastoma line derived from an hGFAP-Cre+;   
p53lox/lox; Ptenlox/+ GEMM by 90%. The same concentration 
(10 µM) had negligible effects on the growth of an 
astrocyte line derived from the hGFAP-Cre+; p53lox/lox 
GEMM (Figure 2E). Similar results were observed in 
the NF1 p53 GEMM [29], where haloperidol induced a 
20% viability reduction in the astrocyte line derived from 
an hGFAP-Cre+; NF1flox/flox GEMM and a 80% viability 
Figure 1: DRD2 is required for glioblastoma growth. (A) Schema of genome-wide shRNA screen. Cells were serially passaged 
after infection with virus containing shRNA constructs. The relative abundance of each shRNA prior to and after passages was subsequently 
determined (see Methods). (B) Cy5 signal for each gene from three independent U87MG screens (denoted as A, B or C) was plotted against 
each other (on x-, y-, and z- axes, respectively). High degrees of correlation were seen (R2=0.89-0.92). Similar degrees of correlations were 
seen for Cy3 signals and for other cell lines. (C) PANTHER pathway analysis of pro-proliferative genes for U87MG and A172. * denotes 
p < 0.05. (D) PANTHER curated DRD2 pathway genes. * denotes pro-proliferative genes identified in our screen. (E) DRD2 silencing 
by independent sh-/siRNAs compromised clonogenic U87MG growth in vitro. Efficiency of DRD2 silencing was determined by RT-PCR 
(bottom panel). Cells were seeded at ~50% confluency, transfected or infected with siRNA or shRNA constructs for 48 hrs and re-plated 
in serial dilution for clonogenic survival assessment. (F) Clonogenic growth inhibition of long- and short-term passaged, patient-derived 
glioblastoma lines by haloperidol. Cells were incubated with haloperidol at the indicated concentrations for the duration of the clonogenic 
assay. (G) Multiple DRD2 antagonists suppressed U87MG clonogenic growth. S: spiperone (5 µM, 10 µM), H: haloperidol (5 µM, 10 µM), 
R: risperidone (10 µM, 25 µM), L: L-741,626 (10 µM, 25 µM). Cells were incubated with DRD2 antagonists at the indicated doses for the 
duration of the clonogenic assay. (H) DRD2 knockdown abolished U87MG subcutaneous xenograft growth. Top: 3×105 cells transduced 
with inducible shRNA2 against DRD2 were injected subcutaneously into the flanks of Nu/Nu mice. 7 days later, the mice were randomized 
to drinking water with or without doxycycline (1 mg/ml). Tumor size was monitored every 5-7 days. Bottom: Inducible shRNA silencing 
of DRD2.  U87MG cells with a stably integrated, inducible shRNA construct were treated with doxycycline or vehicle for 72 hrs. RNA 
was then extracted and DRD2 RT-PCR was performed. (I) Expression of an shRNA resistant form of DRD2 (termed DRD2RR) suppressed 
the anti-proliferative effects of shDRD2 in vivo. Top: U87MG cells transduced with shRNA2 were transfected with DRD2 or DRD2RR, 
and injected subcutaneously. 7 days post-injection, the mice were fed doxycycline (1 mg/ml) containing water. Tumor size was monitored 
every 5-7 days. Bottom: DRD2RR expression is resistant to the DRD2 silencing effects of shRNA2.  U87MG cells with stably integrated 
shRNA2 and transfected with DRD2 or DRD2RR (noted here as RR) were treated with doxycycline for 72 hrs. Whole cell lysates were 
prepared from these cells for DRD2 immuno-blotting. Oncotarget 885 www.impactjournals.com/oncotarget
reduction in the glioblastoma line derived from a hGFAP-
Cre+; p53-/-; NF1flox/flox GEMM. These results suggest a 
therapeutic window for haloperidol in the treatment of 
glioblastoma.  
Previous reports suggest that DRD2 signaling leads 
to ERK activation [23-25, 32]. We hypothesized that this 
signaling may contribute to the pro-proliferative effect of 
DRD2. Supporting this hypothesis, independent DRD2 
antagonists suppressed pERK accumulation in U87MG 
(Figure 3A) by at least an order of magnitude. Suppression 
of pERK accumulation was also observed after 
doxycycline-induced DRD2 shRNA knockdown (Figure 
3B). Importantly, the suppressive effect of shDRD2 on 
pERK was abrogated by expressing an RNAi resistant 
form of DRD2, DRD2RR (Figure 3B). Dose-dependent 
pERK suppressive effects were similarly observed in a 
GSC line, CMK3 [33] (Figure 3C). Further supporting this 
hypothesis, treatment with quinpirole, a DRD2 agonist, 
induced a 3-fold increase in pERK level (Figure 3D) and a 
similar increase in the proliferation rate of the CMK3 line 
(Figure 3D). These results suggest that DRD2 contributes 
to mitogenic signaling in glioblastomas.
Signaling through DRD2 is tightly coupled to the 
activation of heterotrimeric G proteins [34-36]. Among 
these proteins, GNAI2 was previously shown to physically 
interact with DRD2 [34-36]. GNAI2 was also identified as 
a pro-proliferative gene in our genome-wide screen (Figure 
1C) and was over-expressed in clinical glioblastoma 
specimens (Figure 3E). Moreover, the expression levels 
of GNAI2 in TCGA glioblastomas correlated well with 
Figure 2: Increased DRD2 expression in glioblastoma specimens. (A) Overexpression of DRD2 mRNA in glioblastoma 
specimens relative to surrounding normal brain tissues. DRD2 mRNA expression was analyzed using qPCR; matched normal-glioblastoma 
specimens from five patients were tested. T: Tumor; N: Normal brain. (B) DRD2 protein expression was confirmed using three additional 
matched glioblastoma/normal brain pairs by immuno-blotting. T: Tumor; N: Normal brain. Tubulin: loading control. The ratio of DRD2 to 
tubulin was quantitated and shown in the bottom panel. (C) Increased expression of DRD2 in GEMM glioblastoma lines. DRD2 mRNA 
expression was assessed by qPCR. DRD2 mRNA level in a glioblastoma line derived from hGFAP-Cre+; p53-/-; NF1flox/flox (noted as 
p53-/-NF1-/-) GEMM [29] was compared to that in an astrocyte line derived from the hGFAP-Cre+; NF1flox/flox (noted as NF1-/-) GEMM. 
DRD2 mRNA level in a glioblastoma line derived from hGFAP-Cre+; p53lox/lox; Ptenlox/+GEMM (noted as p53 -/-Pten +/-) GEMM [30] was 
compared to that in an astrocyte line derived from an hGFAP-Cre+; p53lox/lox GEMM (noted as p53-/-).  (D) Elevated DRD2 expression in 
glioblastomas formed in vivo in Gtv-a Ink4a-Arf-/- mice stereotactically injected with RCAS-PDGFB-HA [31]. This expression level was 
compared to the contra-lateral normal cortex.  Three sets of matched cortex/glioblastoma specimens are shown. For all qPCRs, the results 
were normalized to 18S rRNA. Comparable results were obtained when normalized to actin or GAPDH. (E) Sensitivity of GEMM derived 
glioblastoma and astrocyte lines to haloperidol. Glioblastoma lines were more sensitive to haloperidol relative to astrocyte lines. Cells were 
seeded at ~50% confluency and treated with 10 µM haloperidol for 5 days. Viability was determined using the CellTiter-Blue viability 
assay (Promega).Oncotarget 886 www.impactjournals.com/oncotarget
those of DRD2 (Supplemental Figure 1). In these contexts, 
we hypothesized that the proliferative effects of DRD2 
signaling may be mediated through GNAI2. Supporting 
this hypothesis, transfection of independent siRNAs 
targeting GNAI2 consistently suppressed U87MG growth 
as well as pERK accumulation (Figure 3F). 
If the mitogenic effects of DRD2 were mediated 
through GNAI2, silencing of GNAI2 should suppress the 
pro-proliferative effects of DRD2 agonists. Consistent 
with these predictions, pre-treatment with GNAI2 siRNA 
(siGNAI2) suppressed the pro-proliferative effects of 
quinpirole (Figure 3G). However, this suppression was 
incomplete when compared to the growth inhibitory effects 
of GNAI2 silencing, indicating that the pro-proliferative 
effects of quinpirole may be mediated through additional 
GNAI2-independent mechanisms.  
Figure 3: DRD2 signaling through a GNAI2-Rap1-ERK axis. (A) DRD2 antagonists decreased pERK accumulation in the 
U87MG glioblastoma cell line. D: DMSO. S: spiperone (5 µM), H: haloperidol (5 µM), R: risperidone (10 µM), L: L-741,626 (10 µM). 
Cells were treated with the various antagonists for 1 hr before lysis/immuno-blotting. (B) Decreased pERK activation by DRD2 shRNA 
can be rescued by expression of an RNAi resistant form of DRD2 (DRD2RR). U87MG lines harboring a doxycycline inducible shDRD2 
construct and pCMV6-DRD2RR or pCMV6 were treated with vehicle or doxycycline (1 µg/ml) for 48 hrs before lysis. Bottom panel: 
quantitative ratio of pERK to ERK. (C) DRD2 antagonists decreased pERK accumulation in the patient-derived CMK3 GSC line in a 
dose-dependent manner. D: DMSO. S: spiperone. H: haloperidol. CMK3 was treated with the various antagonists for 1 hr before lysis. 
(D) Treatment with a DRD2 agonist, quinpirole, enhanced pERK accumulation (left upper). CMK3 was treated with quinpirole for 1 hr 
prior to lysis/immuno-blotting. Lower panel: quantitative ratio of pERK to ERK. Quinpirole promoted cellular growth in the CMK3 GSC 
line detected by CellTiter-Blue (right). Cells were treated with 10 µM quinpirole for 5 days. (E) qPCR analysis revealed increased GNAI2 
mRNA expression in glioblastoma specimens relative to the surrounding normal brain. 5 matched normal-glioblastoma specimens are 
shown. N: normal brain; T: glioblastoma tumor specimens. GNAI2 mRNA level was normalized to 18S rRNA mRNA. Similar results 
were obtained when normalized to actin or GAPDH.  (F) GNAI2 siRNA transfection compromised proliferation of U87MG cells (top) and 
reduced pERK accumulation (bottom). #1 and #2 denotes two independent siRNAs against GNAI2. Cells were seeded at ~50% confluency, 
transfected with siRNAs for 48 hrs, and re-plated in serial dilution for clonogenic survival assessment. (G) The pro-proliferative effect of 
quinpirole in the patient-derived 1123 GSC line was inhibited by GNAI2 silencing. Cells were transfected with siGNAI2s for 48 hrs prior 
to treatment with 10 µM quinpirole for 5 days. Viability was determined using CellTiter-Blue (Promega).  (H) GNAI2 silencing inhibited 
quinpirole-induced pERK accumulation and reversed quinpirole-suppression of Rap1-GTP accumulation in U87MG cells. Cells were 
transfected with siRNAs for 48 hrs prior to the treatment with 10 µM quinpirole for 1 hr.Oncotarget 887 www.impactjournals.com/oncotarget
Activation of GNAI2 recruits Rap1 GTPase-
activating protein (Rap1GAPII) to decrease the 
concentration of GTP-bound Rap1 [37]. Since GTP-
bound Rap1 antagonizes the function of Ras, an upstream 
activator of ERK [37, 38], this mechanism may contribute 
to DRD2-mediated ERK activation. The model predicts 
that quinpirole treatment should suppress the level of 
Rap1-GTP (through activation of Rap1GAPII) and 
induce pERK accumulation. Moreover, these suppressive 
effects should be reversed by silencing of GNAI2 
(which decreases Rap1GAPII activation). Supporting 
this hypothesis, quinpirole treatment reduced the level 
of Rap1-GTP by approximately 3-fold (Figure 3H, lanes 
5 versus 1). This effect was accompanied by pERK 
accumulation. The effects of quinpirole on Rap1-GTP 
suppression and pERK accumulation were abolished when 
quinpirole was added after pre-treatment with independent 
siGNAI2s.  
Another important pathway that signals to Ras/
ERK involves the Epidermal Growth Factor Receptor 
(EGFR) [7, 39]. Since this axis is frequently hyperactive 
in glioblastomas [7] and specific EGFR inhibitors have 
undergone clinical trial [12], we examined whether 
synergy can be derived by co-treatment with an EGFR 
inhibitor, AG1478, and haloperidol. Using the Chou-
Talalay method [40], we demonstrated in vitro synergy 
between these agents in two glioblastoma models:   
U87MG and 1123 [41] (Figure 4A and B). Combination 
index (CI) values were 0.32 in U87MG cells and 0.29 in 
the 1123 GSC line.
 In the subcutaneous U87MG xenograft model, 
AG1478 or haloperidol, at the concentrations tested, 
Figure 4: Haloperidol enhances the tumoricidal effect of the EGFR inhibitor, AG1478. (A) Haloperidol enhanced the 
tumoricidal effect of the EGFR inhibitor, AG1478, against the U87MG glioblastoma line in vitro (top).  Cells were treated with the various 
agents for 5 days; viability was determined using CellTiter-Glo (Promega). The enhanced tumor kill correlated with pERK reduction 
(bottom). For the pERK analysis, cells were treated with the various agents for 1 hr before lysis/immuno-blotting. Combination index (CI) 
value was 0.32 in U87MG cells using the Chou-Talalay method. (B) Haloperidol enhanced the tumoricidal effect of the EGFR inhibitor, 
AG1478, against the 1123 GSC line in vitro (top). The enhanced tumor kill correlated with pERK reduction (bottom). Cells were treated 
as described above and viability was measured using CellTiter-Blue (Promega). CI value was 0.29 in 1123 GSCs using the Chou-Talalay 
method. (C) Combined effect of haloperidol and AG1478 on subcutaneous U87MG xenograft growth. Nu/Nu mice were injected with 
U87MG cells subcutaneously. 8 days later the mice were randomized to: vehicle (n=7), haloperidol (10 mg/kg, n=8), AG1478 (10 mg/
kg, n=8) or combined haloperidol/AG1478 treatment (n=8). *: P<0.05. (D) Combined effect of haloperidol and AG1478 on an orthotopic 
1123 mouse model in vivo. 7 days after intracranial injection with the 1123 GSCs (1x104 cells), Nu/Nu mice were treated daily by oral 
gavage with vehicle (n=5), AG1478 (10 mg/kg, n=5), haloperidol (10 mg/kg, n=5) or combined AG1478/haloperidol (n=5). All xenograft 
experiments were repeated three times.  Representative data are shown. *: P<0.05. (E) Synergistic effect of AG1478 and haloperidol in 
suppressing pERK in vivo. 3 weeks after intracranial injection with 1123, Nu/Nu mice were treated with vehicle, AG1478 (10 mg/kg), 
haloperidol (10 mg/kg), or combined AG1478/haloperidol for 2 hrs, followed by tumor dissection. Whole cell lysates were analyzed for 
pERK and pAKT levels, with Ku86 as loading control. The quantitative ratios of pERK to ERK are shown in the right panel.Oncotarget 888 www.impactjournals.com/oncotarget
minimally delayed tumor growth. Combined AG1478/
haloperidol  treatment,  however,  significantly  delayed 
tumor growth. By post-treatment day 37, the average 
xenograft volume in the combined treatment group was 
~17% of that in the vehicle treated mice (p<0.05). In 
contrast, the average xenograft volumes of the AG1478- 
and haloperidol-treated groups were 85% and 49% of 
the vehicle treated group, respectively (Figure 4C).   
Importantly, none of the treated mice showed weight 
loss or other physical manifestations of systemic toxicity 
relative to the vehicle treated mice. 
We next tested the efficacy of the combination in 
an orthotopic intracranial model. The 1123 xenograft 
was selected because it better recapitulates the histology, 
invasiveness, and molecular physiology of clinical 
glioblastoma than the intracranial U87MG xenograft 
[41]. In this model, we observed the same pattern of 
therapeutic response, with only the combined treatment 
exerting a significant overall survival benefit. All of the 
vehicle-, AG1478-, or haloperidol- treated mice expired 
by approximately day 26 post-implantation. In contrast, 
50% the combined treatment group survived beyond 45 
days (p<0.05) (Figure 4D).  
To test the effect of the combined treatment on 
pERK accumulation in vivo, mice were orthotopically 
implanted with 1123 GSCs and administered vehicle, 
AG1478, haloperidol, or combined AG1478/haloperidol 
treatment after xenograft formation. Tumors were 
extracted 2 hrs after drug infusion and analyzed. These 
results indicate that the combination of AG1478 and 
haloperidol synergistically suppressed pERK accumulation 
in vivo (Figure 4E). 
In sum, our results showed integrated mitogenic 
signaling between EGFR and DRD2 in glioblastomas, 
with conceptual implications for a wider range of cross-
signaling between RTKs and neurotransmitter GPCRs 
[42]. Because antagonists of these GPCRs are clinically 
available and cross the blood-brain barrier [43], re-
purposing of these agents for glioblastoma treatment 
warrants consideration. As a proof-of-principle, we 
demonstrated therapeutic synergy between an EGFR 
inhibitor and a DRD2 antagonist, haloperidol, against 
glioblastomas using independent models.  Interestingly, 
clinical series  have suggested patients undergoing anti-
psychotic therapy are less likely to suffer from brain 
cancer [44]. The clinical familiarity with haloperidol 
and its FDA approved status should facilitate ease of 
clinical translation. Moreover, the doses of haloperidol 
administered in the murine models translate into 
physiologic serum concentrations achievable in the 
clinical setting [45]. Nevertheless, it is important to 
note the superior in vitro and in vivo effects of DRD2 
silencing in glioblastoma ablation relative to haloperidol. 
This discrepancy suggests DRD2 may contribute to 
glioblastoma growth through mechanisms unaffected by 
haloperidol. Insights into these mechanisms should afford 
novel therapeutic opportunities. Our results further suggest 
that other FDA approved, blood-brain barrier-penetrating 
antagonists against GPCR neurotransmitter receptors 
[34] warrant consideration as potential glioblastoma 
therapeutic agents. 
METHODS
Cell lines and Reagents
Human glioblastoma cell lines (U87MG, A172, 
LN18, T98G) and human lung cancer cell lines (A549, 
H460) were purchased from ATCC. NHA was purchased 
from ScienCell. The BT74 GSC line was provided by C. 
David James (University of California, San Francisco, 
CA). The 1123 GSC line was provided by Dr. Ichiro 
Nakano (Ohio State University, Columbus, OH). CMK3 
was established as a glioblastoma GSC line derived from 
a patient specimen and underwent <10 passages before 
use. Glioblastoma specimens and matched contra-lateral 
cortex derived from Gtv-a Ink4a-Arf-/-/RCAS-PDGFB-
HA GEMM mice [31] were kindly provided by Dr. Oren 
Becher (Duke University Medical Center). The hGFAP-
Cre+; p53lox/lox; Ptenlox/+ glioblastoma line and hGFAP-
Cre+: p53lox/lox astrocyte line were described in [30] and 
provided by Dr. Frank Furnari (Ludwig Institute for 
Cancer Research, San Diego). The hGFAP-Cre+;NF1flox/flox 
astrocyte and hGFAP-Cre+; p53-/-; NF1flox/flox glioblastoma 
lines were described in [29] and kindly provided by Dr. 
Chang-Hyuk Kwon (Ohio State University Medical 
Center). All adherent glioblastoma lines were grown at 37 
°C with 5% CO2, passaged with trypsin and maintained in 
complete DMEM media (DMEM, 10% FBS (Invitrogen) 
and 1% penicillin-streptomycin (Gibco)). All GSC lines 
were maintained in mouse/human NeuroCult medium 
(Stem Cell Technology) supplemented with EGF, FGF 
and heparin according to the manufacturer’s instructions. 
NHA cells were passaged using Astrocyte Medium 
from ScienCell. DRD2 antagonists haloperidol (H), 
spiperone (S), risperidone (R), and L-741,626 (L), and 
agonist quinpirole were obtained from Tocris Bioscience. 
RNAiMax and Lipofectamine 2000 were obtained from 
Invitrogen.  Polybrene was purchased from Sigma.
The experiments involving DRD2 antagonists or 
sh-/siRNAs were performed in complete DMEM media 
or in neurosphere media supplemented with EGF, FGF 
and heparin. DRD2 antagonists were added for 1 hr for 
the immuno-blotting experiments and for 5-7 days for the 
viability experiments. For experiments involving siRNAs, 
cells were transfected with siRNAs for 48 hrs prior to 
subsequent manipulations. For experiments involving 
shRNAs, cells were transduced with viral shRNA 
constructs for 3-5 days prior to subsequent manipulations. 
For inducible shRNA constructs, transduced cells were Oncotarget 889 www.impactjournals.com/oncotarget
treated with or without doxycycline at 1 µg/ml for 5 days 
before subsequent manipulations. 
Experiments involving quinpirole treatment were 
performed in DMEM with 1% serum or neurosphere 
media without EGF/FGF supplementation. For viability 
experiments, quinpirole (10 µM) was added for 5-7 days.   
For pERK related experiments, lysates were prepared after 
1 hr of quinpirole treatment. Cell viability was measured 
using CellTiter-Glo luminescent cell viability assay kit 
(Promega) for the adherent lines, CellTiter-Blue cell 
viability assay (Promega) for the neurosphere cultures, or 
by clonogenic assays [46]. 
Genome-wide shRNA screen
The screen was performed essentially as previously 
described [17]. In brief, the Hannon-Elledge whole 
genome pooled shRNA library with 74,705 different 
MSCV-PM  retroviral  shRNA  constructs  targeting 
human open reading frames was used. The library was 
split into six pools. For each pool, three replicates of at 
least 1.3x107 cells of A549, NCI-H460, U87MG, and 
A172 cells were incubated with an equivalent number 
of retroviral colony-forming units in media containing 8 
µg/ml polybrene (Sigma-Aldrich). Sufficient cells were 
infected for a 1000-fold representation of each shRNA 
sequence at a multiplicity-of-infection (MOI) of 1. After 
selection for stable integrants using 1 µg/ml puromycin, 
cells were passaged for a total of 12 population doublings 
(PD), at all times maintaining a minimum of 1.3 x107 cells 
per replicate. Genomic DNA was extracted from cells 
harvested both before (PD0) and after the 12 population 
doublings (PD12). Half-hairpin shRNA-containing 
sequences were amplified by PCR, purified by agarose 
gel electrophoresis and labeled with Cy5 (PD0) or Cy3 
(PD12). Competitive hybridization to custom Agilent 
microarrays was performed to determine the relative 
abundance of each shRNA. The genomic DNA from each 
triplicate experiment was analyzed on different days.   
The results of the triplicates were assessed by Pearson 
correlation analysis.
Scoring was performed as described previously [47]. 
Briefly, the mean log2 (Cy3/Cy5) ratio was determined for 
each shRNA sequence using triplicate data. shRNAs with 
standard deviation of log2 (Cy3/Cy5) ratios greater than 
the absolute mean log2 (Cy3/Cy5) ratio were excluded 
from further analyses to reduce false positive hits. For 
each gene, one point was assigned for each different 
shRNA sequence for which the mean log2 (Cy3/Cy5) ratio 
was less than or equal to -1. One half point was assigned 
for each shRNA sequence for which the mean log2 (Cy3/
Cy5) ratio was less than or equal to -0.5. A negative point 
was assigned for each shRNA sequence for which the 
mean log2 (Cy3/Cy5) ratio was greater than or equal to 
+1, and a negative half point was assigned for each shRNA 
sequence for which the mean log2 (Cy3/Cy5) ratio was 
greater than or equal to +0.5, to penalize discordant 
results among shRNA sequences targeting a particular 
gene. Genes were ranked based on descending total score, 
with higher rankings given to genes with equivalent total 
scores but fewer different shRNA sequences targeting the 
gene. The top 1,000 genes on this list were analyzed by 
PANTHER pathway analysis (http://www.pantherdb.org/).
Constructs, Transfection, and Transduction
siRNAs against DRD2 were obtained from Qiagen 
(DRD2 siRNA #1: GCAACGTGCTGGTGTGCAT; 
DRD2 siRNA #2: GGGCAGTGCTAGTGAGCTG). 
GNAI2 siRNAs were obtained from Qiagen (GNAI2 
siRNA #1: GGAGCGTATTGCACAGAGT; GNAI2 
siRNA #2, GACCATCTGCTTCCCTGAG). Cells were 
transfected with siRNAs using Lipofectamine according 
to manufacturer’s instructions.
DRD2 shRNAs were provided by the Dana-Farber 
Cancer Institute Core RNAi facility: DRD2 shRNA #1: 
GTATCCCTTCTCACAGCACAT; DRD2 shRNA#2: 
GCCCTTCTTCATCACACACAT. Lentiviral shRNA 
particle production and infection with a low MOI < 
5 were performed according to the manufacturer’s 
instructions and stable cells were generated by selection 
with puromycin (1 µg/ml) for 5 days prior to further 
experiments.
For construction of an RNAi resistant form of 
DRD2 against shRNA#2, a full-length DRD2 clone 
(pCMV6-DRD2-tGFP)  was  purchased  from  OriGene 
and validated by direct DNA sequencing. The following 
sequence (G CCC TTC TTC ATC ACA CAC AT) was 
mutated to (G CCC TTT TTT ATA ACA CAC AT) 
using the QuickChange II mutagenesis kit (Stratagene) 
according to manufacturer’s instructions. Final constructs 
were confirmed by sequencing. The pLKO.1-Tet vector 
(Addgene) was used for inducible shDRD2 experiments.  
RT-PCR and real time Q-PCR  
Total RNA was extracted using a previously 
described Trizol-based method [48] followed by cDNA 
synthesis using iScript supermix (Bio-Rad). q-PCR 
was performed and analyzed as previously described 
[49]. The primers used included: DRD2 forward: 5’ 
GCGGACAGACCCCACTACAA 3’ and reverse: 5’ 
AAGGGCACGTAGAAGGAGAC 3’; HPRT forward: 
5’ CAGGACTGAACGTCTTGCTC 3’; and reverse: 5’ 
CAAATCCAACAAAGTCTGGC 3’. 
Real time Q-PCR was conducted using primers:   
DRD2 Forward: 5’ CTCTTCGGACTCAATAACGCA 
3’ and Reverse: 5’ GACGATGGAGGAGTAGACCAC 
3’; GNAI2 Forward: 5’ TACCGGGCGGTTGTCTACA 
3’ and Reverse: 5’ GGGTCGGCAAAGTCGATCTG 3’; 
Actin Forward: 5’TGAAGTGTGACGTGGACATC 3’ Oncotarget 890 www.impactjournals.com/oncotarget
and Reverse: 5’GGAGGAAGCAATGATCT 3’; 18s rRNA 
Forward: 5’TACCACATCCAAGGAAGGCAGCA 3’ 
and Reverse: 5’ TGGAATTACCGCGGCTGCTGGCA3’. 
GAPDH Forward: 5’ATCATCCCTGCCTCTACTGG 3’ 
and Reverse: 5’GTCAGGTCCACCACTGACAC 3’.
Immuno-blotting and Rap1 pull down assay
After treatment with DRD2 antagonists or agonist 
for 1 hr, cells were lysed in RIPA buffer containing 
20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 
1% Triton-X 100, 20 mM β-glycerophosphate and 1 mM 
p-amidinophenyl methanesulfonyl fluoride hydrochloride 
supplemented with Complete protease inhibitor cocktail 
(Roche) and PhosSTOP phosphatase inhibitor cocktail 
(Roche). After sonication in short 1-3 second pulses for 
10 times using the 3mm probe set, lysates were cleared 
by centrifugation at 12,000 rpm for 10 min, and analyzed 
by immuno-blotting analysis. Antibodies used included:   
DRD2 (1:1000, Millipore); pERK (1:2000), ERK 
(1:2000), pAKT473 (1:2000), pS6 (1:2000), and pSTAT3 
(1:1000) from Cell Signaling Technology; GNAI2 
(1:1000, Proteintech); Tubulin (1:5000, Sigma); Ku86 
(1:1000, Santa Cruz Biotechnology). 
For the RNAi rescue experiment, U87MG 
cells transduced with inducible shDRD2 were further 
transduced with vector or shRNA-resistant DRD2RR 
followed by appropriate antibiotic selection. Doxycycline 
(1 µg/ml) treatment was carried out for 48 hrs before cell 
lysis.  For the in vivo xenograft experiments, Nu/Nu mice 
were injected with 1x104 cells. 3 weeks after implantation, 
mice were treated with vehicle, AG1478 (10 mg/kg), 
haloperidol (10 mg/kg), or combined AG1478/haloperidol 
for 2 hrs. The mice were then sacrificed, and the tumors 
were dissected for lysate preparation as previously 
described [46].  
The Rap1 activation assay was conducted according 
to the manufacturer’s instructions (Thermo Scientific). 
Briefly, after transfection with siRNA control or GNAI2 
siRNAs for 48 hrs, U87MG cells were treated with or 
without quinpirole (10 µM) for 1 hr. Total cell lysates 
(500 µg) from each treatment were incubated with agarose 
beads pre-bound with RalGDS-RBD (Rap1-binding 
domain) which binds specifically to GTP-bound-Rap1 
(incubation for 1 hr at 4°C with gentle rotation). Bound 
protein was eluted with Laemmli buffer and analyzed by 
immuno-blotting.  
Tumor and normal human specimens 
All research performed was approved by the IRB at 
the University of California, San Diego Human Research 
Protections Program and was in accordance with the 
principles expressed at the Declaration at Helsinki. Each 
patient was consented by a dedicated clinical research 
specialist prior to collection. Written consent was obtained 
for each patient. The consent process was approved by the 
ethics committee, and all records were documented in 
our electronic record system. The written consent from 
patients was also scanned into our electronic filing system. 
The specimens were collected under IRB 120345X. 
Pathological analysis of the specimens was performed 
to verify > 80% tumor cell content by a board certified 
neuro-pathologist. 
Subcutaneous and orthotopic xenograft models
U87MG cells (3x105 cells in 50 µl for shRNA 
experiments and 1x106 cells in 50 µl for antagonist 
experiments) were injected subcutaneously into the flanks 
of Nu/Nu mice (~7 weeks old) purchased from Charles 
River Laboratories. The mice were randomized into 4 
groups of 7-8 mice: vehicle, haloperidol, AG1478, or 
combined haloperidol/AG1478 treatment. AG1478 and 
haloperidol were injected i.p. daily starting 8 days after 
xenograft implantation.  Daily injections took place for 30 
days. Tumor volume was calculated based on the formula: 
volume = (width)2 x length/2 every 5-7 days. Mice were 
sacrificed when they developed tumors measuring greater 
than 2.0 cm in diameter. Mice were weighed weekly. 
No significant weight changes were found in the treated 
versus non-treated groups. For experiments involving 
doxycycline, doxycycline was dissolved at 1 mg/ml in 
drinking water with 5% sucrose and given to mice starting 
7 days after tumor implantation.
Orthotopic mouse model were conducted in 
accordance with the ‘National Institutes of Health Guide 
for the Care and Use of Laboratory Animals’ (NIH 
publication 80-23). Dissociated GSCs (1x104 cells in   
4 µl HBSS) were stereotactically injected into the brains 
of the nude mice at age 5-6 weeks old. The coordinates 
were: 1.8 mm to the right of bregma and 3 mm deep 
from the dura. Starting on day 8, mice received oral 
administrations of haloperidol (10 mg/kg), AG1478 
(10 mg/kg), or both by daily oral gavage. Control mice 
received 0.5% hydroxypropylmethylcellulose and 0.1% 
Tween-80 vehicle treatment. Mice with >20% reductions 
in body weight were sacrificed, and brains were processed 
for paraffin or frozen section. 
Statistical analyses
Data are presented as means with their respective 
standard errors (SEM) or as statistical scatter plots 
generated using GraphPad Prism 5. Student’s t test 
(two-tailed) was used unless otherwise indicated. For 
survival curves, p values were analyzed using the log-
rank (Mantel-Cox) test. P  <  0.05 was considered to be 
statistically significant.Oncotarget 891 www.impactjournals.com/oncotarget
TCGA glioblastoma transcriptomal analysis
TCGA glioblastoma transcriptomal profiles were 
downloaded from TCGA Data Portal (http://tcga-data.
nci.nih.gov/tcga/). Level 3 normalized, Agilent 244K 
gene expression mRNA array data was downloaded and 
gene expression values were median centered. A heat 
map showing the expression patterns of DRD2, EGFR, 
and GNAI2 was generated using TIGR Multiexperiment 
Viewer (http://www.tm4.org/mev.html). Transcriptomal 
subtypes of glioblastoma were determined as previously 
described [7].
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